The DCB develops new drugs either independently or collaboratively with academia and industry. To date, the DCB has obtained over 10 investigational New Drug application approvals and has successfully transferred to the industry through licensing. Accordingly, these drugs are under development through clinical trials. DCB can perform commissioned research on developing new drugs and offer customized services to help accelerate the commercialization of new drugs.